HIV molecular immunology database

 

Search Antibody Database

Found 1 matching record:

Displaying record number 612

Download this epitope record as JSON.

MAb ID D20
HXB2 Location Env Env Epitope Map
Author Location gp120( IIIB)
Research Contact P. Earl, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD
Epitope
Ab Type gp120 CD4BS
Neutralizing  
Species (Isotype) mouse(IgG)
Patient  
Immunogen vaccine
Keywords antibody binding site, antibody generation

Vaccine Details

Vaccine type vaccinia
Vaccine strain B clade IIIB
Vaccine component oligomeric gp140

Notes

Showing 6 of 6 notes.

References

Showing 6 of 6 references.

Isolation Paper
Earl1994 P. L. Earl, C. C. Broder, D. Long, S. A. Lee, J. Peterson, S. Chakrabarti, R. W. Doms, and B. Moss. Native oligomeric human immunodeficiency virus type 1 Envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol., 68:3015-3026, 1994. In a study of the repertoire of response to oligomeric versus monomeric Env protein, 138 murine MAbs were generated in response to an immunogen that was a gp120/bp41 oligomeric molecule that was not cleaved due to a mutation in the cleavage site. The oligomeric molecule was found to elicit a response that was very different than the monomer. Most MAbs were conformational, many were to gp41 or if in gp120, to the CD4 BS. Few MAbs to linear V3 epitopes were produced in response to oligomeric protein, though this was a common specificity in response to immunization with gp120 monomeric protein. PubMed ID: 7512157. Show all entries for this paper.

Broder1994 C.C. Broder, P.L. Earl, D. Long, S.T. Abedon, B. Moss, and R.W. Doms. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: Oligomer-specific and -sensitive monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A., 91:11699-11703, 1994. 35 anti-gp41 and 27 anti-gp120 murine MAbs generated by immunization with oligomeric HIV-1 IIIB envelope were studied. These MAbs tended to react with conformational epitopes. 21 of the anti-gp41 MAbs reacted preferentially with oligomeric env, while only 1 of the anti-gp120 MAbs reacted more strongly with the oligomer, and 14 of the anti-gp120 preferentially recognized monomeric env. PubMed ID: 7972127. Show all entries for this paper.

Earl1997 P. L. Earl, C. C. Broder, R. W. Doms, and B. Moss. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol., 71:2674-84, 1997. PubMed ID: 9060620. Show all entries for this paper.

Otteken1996 A. Otteken, P. L. Earl, and B. Moss. Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 Envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J. Virol., 70:3407-15, 1996. PubMed ID: 8648672. Show all entries for this paper.

Richardson1996 T. M. Richardson, Jr., B. L. Stryjewski, C. C. Broder, J. A. Hoxie, J. R. Mascola, P. L. Earl, and R. W. Doms. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J. Virol., 70:753-62, 1996. An Env antigen capture enzyme-linked immunosorbent assay using a soluble, oligomeric form of HIV-1IIIB Env (gp140) that contains gp120 and the gp41 ectodomain was developed. The gp140, captured by various monoclonal antibodies (MAbs), retained its native oligomeric structure: it bound CD4 and was recognized by MAbs to conformational epitopes in gp120 and gp41, including oligomer-specific epitopes in gp41. PubMed ID: 8551612. Show all entries for this paper.

Sugiura1999 W. Sugiura, C. C. Broder, B. Moss, and P. L. Earl. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins. Virology, 254:257-67, 1999. PubMed ID: 9986792. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health